Medicare Negotiation Workarounds: Lilly’s Ricks On Big Pharma Strategies For Small Molecule Drugs

 
• By Cathy Kelly

A vocal critic of the way Medicare price negotiation program treats small molecule drugs, the Lilly CEO and offers possible scenarios of how developers may react.

Lots Of Strategizing Going On • Source: Shutterstock

More from Market Access

More from Pink Sheet